B
ACAD icon

Braidwell’s Acadia Pharmaceuticals ACAD Stock Holding History

Braidwell’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.7M Sell
1,646,399
-824,800
-33% -$18.1M 1.54% 23
2026
Q1 		$55M Buy
2,471,199
+439,178
+22% +$10.5M 1.84% 18
2025
Q4 		$54.3M Sell
2,032,021
-346,634
-15% -$8.28M 1.74% 18
2025
Q3 		$50.8M Buy
+2,378,655
New +$56.3M 1.51% 24
2023
Q1 		– Sell
-1,493,121
Closed -$23.8M – 82
2022
Q4 		$23.8M Buy
+1,493,121
New +$23.3M 0.8% 47

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Braidwell's ACAD Position: Q2 2026 in Review

Braidwell reduced its Acadia Pharmaceuticals (ACAD) stake by 33% in Q2 2026, selling an estimated $18.1M and leaving 1,646,399 shares worth $41.7M. The position accounts for 1.54% of the portfolio, ranked #23.

Braidwell first reported a position in ACAD in Q4 2022 and has held it in 5 quarters since. The position peaked at $55M in Q1 2026. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Braidwell held 1,646,399 shares of Acadia Pharmaceuticals worth $41.7M as of Q2 2026.
  • Braidwell sold 824,800 Acadia Pharmaceuticals shares in Q2 2026, an estimated $18.1M.
  • Acadia Pharmaceuticals made up 1.54% of Braidwell's portfolio in Q2 2026, its #23 holding.
  • Braidwell first reported a position in Acadia Pharmaceuticals in Q4 2022 and has held it in 5 quarters since.
  • Braidwell's Acadia Pharmaceuticals position peaked at $55M in Q1 2026.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.